Connect with us

Life Sciences

Achieving High Resolution LC Separations of Long-mer (>60mer) Oligonucleotides

In this GEN webinar, Dr. Martin Gilar from Waters, will review tools and techniques that improve the resolution of long-mer oligonucleotide separations…

Published

on

This article was originally published by GEN Genetic Engineering and Biotechnology News

Broadcast Date: May 25, 2023
Time: 8:00 am PT, 11:00 am ET, 17:00 CET

As nucleic acid therapeutics continue to expand and diversify, there is a growing need to achieve higher resolution separations of longer oligonucleotides. Specific examples include characterization and impurities analysis of single guide RNA for gene editing (sgRNA; typically 100-150mer), and mRNA polyA tail analysis to characterize polyA tail length and polydispersity (typically in the 90-130mer range).

In this webinar, Dr. Martin Gilar will review tools and techniques that improve the resolution of long-mer oligonucleotide separations and will demonstrate data obtained for both the characterization and impurities analysis of sgRNA as well as polyA tail length and heterogeneity analysis.

A live Q&A session will follow the presentation, offering you a chance to pose questions to our expert panelist.

Martin Gilar
Martin Gilar, PhD
Scientific Fellow:
Separations R&D Group
Waters Corporation

Waters logo

The post Achieving High Resolution LC Separations of Long-mer (>60mer) Oligonucleotides appeared first on GEN – Genetic Engineering and Biotechnology News.


gene editing

Life Sciences

Wittiest stocks:: Avalo Therapeutics Inc (NASDAQ:AVTX 0.00%), Nokia Corp ADR (NYSE:NOK 0.90%)

There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well…

Continue Reading
Life Sciences

Spellbinding stocks: LumiraDx Limited (NASDAQ:LMDX 4.62%), Transocean Ltd (NYSE:RIG -2.67%)

There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well…

Continue Reading
Life Sciences

Asian Fund for Cancer Research announces Degron Therapeutics as the 2023 BRACE Award Venture Competition Winner

The Asian Fund for Cancer Research (AFCR) is pleased to announce that Degron Therapeutics was selected as the winner of the 2023 BRACE Award Venture Competition….

Continue Reading

Trending